• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Bamlanivimab Treatment Leads to Rapid Selection of Immune Escape Variant Carrying the E484K Mutation in a B.1.1.7-Infected and Immunosuppressed Patient.

作者信息

Lohr Benedikt, Niemann Dirk, Verheyen Jens

机构信息

Koblenz Laboratory, Koblenz, Germany.

Gemeinschaftsklinikum Mittelrhein-Ev. Stift St. Martin, Koblenz, Germany.

出版信息

Clin Infect Dis. 2021 Dec 6;73(11):2144-2145. doi: 10.1093/cid/ciab392.

DOI:10.1093/cid/ciab392
PMID:34009286
Abstract
摘要

相似文献

1
Bamlanivimab Treatment Leads to Rapid Selection of Immune Escape Variant Carrying the E484K Mutation in a B.1.1.7-Infected and Immunosuppressed Patient.巴瑞替尼治疗导致一名感染B.1.1.7且免疫抑制的患者快速筛选出携带E484K突变的免疫逃逸变体。
Clin Infect Dis. 2021 Dec 6;73(11):2144-2145. doi: 10.1093/cid/ciab392.
2
Failure of bamlanivimab with selection of E484K mutation in an allogeneic stem cell transplant recipient with nosocomial SARS-CoV-2 infection.同种异体干细胞移植受者院内感染 SARS-CoV-2 后，巴利昔单抗治疗失败并出现 E484K 突变。
Antivir Ther. 2024 Feb;29(1):13596535221097495. doi: 10.1177/13596535221097495.
3
Emergence and onward transmission of a SARS-CoV-2 E484K variant among household contacts of a bamlanivimab-treated patient.在接受巴美洛维单抗治疗的患者的家庭接触者中出现并传播 SARS-CoV-2 E484K 变异株。
Diagn Microbiol Infect Dis. 2022 May;103(1):115656. doi: 10.1016/j.diagmicrobio.2022.115656. Epub 2022 Feb 3.
4
Influence of treatment with neutralizing monoclonal antibodies on the SARS-CoV-2 nasopharyngeal load and quasispecies.中和性单克隆抗体治疗对 SARS-CoV-2 鼻咽负荷和准种的影响。
Clin Microbiol Infect. 2022 Jan;28(1):139.e5-139.e8. doi: 10.1016/j.cmi.2021.09.008. Epub 2021 Sep 16.
5
Limited Neutralization of Authentic Severe Acute Respiratory Syndrome Coronavirus 2 Variants Carrying E484K In Vitro.体外实验中，对携带 E484K 变异的真实严重急性呼吸综合征冠状病毒 2 型的有限中和作用。
J Infect Dis. 2021 Oct 13;224(7):1109-1114. doi: 10.1093/infdis/jiab355.
6
Spike Gene Evolution and Immune Escape Mutations in Patients with Mild or Moderate Forms of COVID-19 and Treated with Monoclonal Antibodies Therapies.刺突基因进化和 COVID-19 轻症或中症患者的免疫逃逸突变与单克隆抗体治疗。
Viruses. 2022 Jan 24;14(2):226. doi: 10.3390/v14020226.
7
Comprehensive mapping of binding hot spots of SARS-CoV-2 RBD-specific neutralizing antibodies for tracking immune escape variants.全面绘制 SARS-CoV-2 RBD 特异性中和抗体的结合热点，用于跟踪免疫逃逸变异株。
Genome Med. 2021 Oct 14;13(1):164. doi: 10.1186/s13073-021-00985-w.
8
Emergence of the E484K mutation in SARS-COV-2-infected immunocompromised patients treated with bamlanivimab in Germany.在德国接受巴瑞替尼治疗的新冠病毒感染免疫功能低下患者中出现E484K突变
Lancet Reg Health Eur. 2021 Sep;8:100164. doi: 10.1016/j.lanepe.2021.100164. Epub 2021 Jul 14.
9
Bamlanivimab infusion experience at one academic emergency department.一家学术性急诊科的巴姆兰尼单抗输注经验。
Am J Emerg Med. 2022 Jun;56:266-267. doi: 10.1016/j.ajem.2021.06.076. Epub 2021 Jul 12.
10
Genomic Evidence of SARS-CoV-2 Reinfection Involving E484K Spike Mutation, Brazil.基因组证据表明巴西出现涉及 Spike 蛋白 E484K 突变的 SARS-CoV-2 再感染。
Emerg Infect Dis. 2021 May;27(5):1522-1524. doi: 10.3201/eid2705.210191. Epub 2021 Feb 19.

引用本文的文献

1
Comparison of Dual Monoclonal Antibody Therapies for COVID-19 Evolution: A Multicentric Retrospective Study.COVID-19 进化的双克隆抗体治疗比较：一项多中心回顾性研究。
Viruses. 2024 Sep 29;16(10):1542. doi: 10.3390/v16101542.
2
COVID-19 Variants and Vaccine Development.新型冠状病毒变异株与疫苗研发。
Viruses. 2024 May 10;16(5):757. doi: 10.3390/v16050757.
3
SARS-CoV-2 resistance to monoclonal antibodies and small-molecule drugs.SARS-CoV-2 对单克隆抗体和小分子药物的耐药性。
Cell Chem Biol. 2024 Apr 18;31(4):632-657. doi: 10.1016/j.chembiol.2024.03.008.
4
Clinical and Virological Outcome of Monoclonal Antibody Therapies Across SARS-CoV-2 Variants in 245 Immunocompromised Patients: A Multicenter Prospective Cohort Study.245例免疫功能低下患者中针对新冠病毒变异株的单克隆抗体疗法的临床和病毒学结果：一项多中心前瞻性队列研究
Clin Infect Dis. 2024 Jun 14;78(6):1514-1521. doi: 10.1093/cid/ciae026.
5
Possible contribution of rare alleles of human ACE2 in the emergence of SARS-CoV-2 variants escaping the immune response.人类 ACE2 稀有等位基因可能有助于逃避免疫反应的 SARS-CoV-2 变异株出现。
Front Immunol. 2023 Oct 10;14:1252367. doi: 10.3389/fimmu.2023.1252367. eCollection 2023.
6
Vaccine effectiveness of the mRNA-1273 3-dose primary series against COVID-19 in an immunocompromised population: A prospective observational cohort study.mRNA-1273 三剂基础免疫程序对免疫功能低下人群 COVID-19 的疫苗有效性：一项前瞻性观察队列研究。
Vaccine. 2023 Jun 1;41(24):3636-3646. doi: 10.1016/j.vaccine.2023.04.075. Epub 2023 May 3.
7
Viral Population Heterogeneity and Fluctuating Mutational Pattern during a Persistent SARS-CoV-2 Infection in an Immunocompromised Patient.免疫功能低下患者持续性 SARS-CoV-2 感染期间的病毒群体异质性和突变模式波动。
Viruses. 2023 Jan 19;15(2):291. doi: 10.3390/v15020291.
8
Expanding the scope and visibility of ambulatory stewardship programs with novel coronavirus disease 2019 (COVID-19) therapeutics.扩大2019年新型冠状病毒病（COVID-19）治疗方案的门诊管理项目的范围和可见度。
Antimicrob Steward Healthc Epidemiol. 2022 Apr 29;2(1):e73. doi: 10.1017/ash.2022.52. eCollection 2022.
9
On variants and vaccines: The effectiveness of Covid-19 monoclonal antibody therapy during two distinct periods in the pandemic.关于变种和疫苗：在大流行的两个不同时期，Covid-19 单克隆抗体治疗的效果。
PLoS One. 2022 Dec 1;17(12):e0278394. doi: 10.1371/journal.pone.0278394. eCollection 2022.
10
The Omicron variant of concern: Diversification and convergent evolution in spike protein, and escape from anti-Spike monoclonal antibodies.关注的奥密克戎变异株：刺突蛋白的多样化和趋同进化，以及逃避抗刺突单克隆抗体。
Drug Resist Updat. 2022 Dec;65:100882. doi: 10.1016/j.drup.2022.100882. Epub 2022 Oct 3.